7Baggers

argenx SE
(NASDAQ:ARGX) 

ARGX stock logo

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia...

Founded: 2008
Full Time Employees: 186
Sector: Healthcare
Industry: Biotechnology
PharmaceuticalsHealthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-05-09 2024-02-29 2023-10-31 2023-06-30 2023-05-05 2023-03-02 2022-12-31 2022-10-27 2022-06-30 2022-05-05 2022-03-02 2021-12-31 2021-06-30 2021-05-14 2020-12-31 2020-10-22 2020-06-30 2020-02-27 2019-12-31 2019-06-30 2018-12-31 2018-08-31 2017-12-31 
                                 
      product net sales
    		1,126,961,000  790,050,000 2,184,434,085,000 572,997,000 269,313,000 398,283,000 374,351,000 329,097,000 269,313,000 218,022,000 173,396,000 56,831,250 131,329,000 74,833,000 21,163,000              
      other operating income*
    		24,377,000                             
      total operating income
    		1,151,338,000  807,370,000 2,250,548,181,000 588,878,000 281,035,000 412,513,000 417,840,000 339,839,000 281,035,000 229,759,000 182,116,000 65,788,000 146,489,000 85,183,000 31,480,000 539,418,000  487,477,000 167,415,000 39,998,000 42,586,000 31,117,000 82,584,000  51,299,000  23,884,000  
      cost of sales
    		-109,426,000  -80,805,000 -227,134,367,000 -59,072,000 -24,024,000 -43,178,000 -39,477,000 -35,999,000 -24,024,000 -18,335,000 -12,786,000 -4,161,500 -10,264,000 -5,010,000 -1,372,000              
      research and development expenses
    		-355,651,000  -309,070,000 -982,736,805,000 -235,940,000 -195,509,000 -224,969,000 -306,373,000 -191,755,000 -195,509,000 -165,855,000 -147,798,000 -128,892,000 -236,681,000 -126,919,000 -151,968,000 -580,520,000  -273,907,000 -122,328,000 48,619,000 -246,284,000 -171,718,000 -197,665,000  -78,304,000  -25,592,000  
      selling, general and administrative expenses
    		-336,291,000  -276,248,000 -1,054,567,608,000 -277,698,000 -161,977,000 -235,995,000 -208,826,000 -191,930,000 -161,977,000 -149,172,000 -135,287,000 -84,211,250 -108,181,000 -127,798,000 -100,866,000 -307,644,000  -129,599,000 -56,253,000 35,811,000 -100,380,000 -61,644,000 -64,569,000  -27,462,000  -5,045,000  
      income from investment in a joint venture
    		-3,776,000  -2,307,000 -7,638,706,000 -1,981,000                         
      total operating expenses
    		-805,144,000  -668,430,000 -2,272,077,486,000 -574,691,000 -383,129,000 -505,934,000 -556,464,000 -420,427,000 -383,129,000 -333,623,000 -296,548,000 -217,264,750 -355,126,000 -259,727,000 -254,206,000 -888,164,000  -403,506,000 -178,580,000 84,430,000 -346,664,000 -233,362,000       
      operating profit/
    		346,194,000  138,940,000 -31,173,750 14,187,000                         
      financial income
    		42,700,000  37,118,000 157,390,586,000 40,586,000 20,441,000 38,895,000 40,308,000 30,049,000 20,441,000 16,588,000 13,925,000 3,435,000 8,007,000 4,912,000 821,000       -2,178,000 14,399,000  7,210,000  9,000  
      financial expense
    		-993,000  -1,135,000 -2,462,240,000 -676,000 -207,000 -512,000 -280,000 -231,000 -207,000 -188,000 -990,000 -729,000 -785,000 -1,178,000         -124,000      
      exchange (losses)/gains
    		-1,848,000                             
      profit/(loss) for the period before taxes
    		386,053,000  202,361,000 -332,250 88,024,000        -172,018,500 -241,024,000 -216,979,000               
      income tax (expense)/benefit
    		-41,795,000  -32,892,000 15,052,000 3,386,000    10,637,000 -10,507,000   4,274,000 5,982,000 8,229,000    -12,835,000           
      profit for the period
    		344,258,000 414,827,000                            
      profit for the period attributable to:
    		                             
      owners of the parent
    		344,258,000  169,469,000 14,719,750 91,410,000 -94,368,000 -61,597,000 -99,172,000 -72,642,000 -94,368,000 -28,871,000 -38,613,000 -167,744,500 -235,042,000 -208,750,000  -408,265,000      -205,637,000       
      weighted-average number of shares used for basic profit per share
    		61,371,508                             
      basic profit per share
    		5.61 6.8                            
      weighted-average number of shares used for diluted profit per share
    		66,441,326                             
      diluted profit per share
    		5.18 6.32                            
      personnel expenses
    		 225,419,000                            
      marketing services
    		 178,240,000                            
      professional fees
    		 105,550,000                            
      bis expenses
    		 21,259,000                            
      supervisory board
    		 8,558,000                            
      facilities and occupancy expenses
    		 8,479,000                            
      depreciation and amortization
    		 3,548,000                            
      other expenses
    		 50,097,000                            
      total selling, general and administrative expenses
    		 601,150,000                            
      1)comparative figures have been presented to be consistent with the one adopted in the company’s latest annual report.
    		                             
      weighted-average number of shares outstanding
    		 61,034,202,000 60,983,325,000 59,855,585,000,000 60,087,498,000 55,828,239,000 59,309,996,000 59,118,827,000 58,128,233,000 55,828,239,000 55,555,186,000 55,364,124,000  55,203,655,000 54,802,339,000 52,084,335,000 51,075,827,000 51,075,827,000 50,638,702,000 49,946,515,000 38,619,121,000 44,717,568,000 43,476,103,000 38,619,121,000 38,619,121,000 37,764,237,000 24,609,536 21,756,366,000  
      weighted-average number of shares outstanding for purpose of diluted profit per share
    		 65,653,007                            
      collaboration revenue
    		  633,000 4,345,095,000 239,000 1,237,000 2,718,000 32,486,000 692,000 1,237,000 1,118,000 764,000 2,315,500 6,652,000 361,000 2,249,000              
      other operating income
    		  16,687,000 61,769,001,000 15,642,000 10,485,000 11,512,000 11,003,000 10,050,000 10,485,000 10,740,000 7,956,000 6,641,250 8,508,000 9,989,000 8,068,000 42,141,000  17,079,000 9,260,000 277,000 12,524,000 8,729,000 12,801,000  7,767,000  1,436,000  
      exchange gains/
    		  27,438,000 1,678,000 33,927,000 -2,001,000 -19,312,000 37,418,000 -32,509,000 -2,001,000 11,165,000  -23,247,750 -39,609,000 -46,169,000 -7,213,000 -50,053,000  -18,375,000           
      profit/(loss) for the period
    		  169,469,000 14,719,750 91,410,000 -94,368,000       -167,744,500 -235,042,000 -208,750,000               
      profit/(loss) for the period attributable to:
    		                             
      basic profit/
    		  2,780 -976.08 1,520 -1,690       -3,102.5 -4,260 -3,810               
      weighted-average number of shares outstanding for diluted profit/(loss) per share
    		  65,664,300                           
      diluted profit/
    		  2.58 -897.22 1,390 -1,690       -3,102.5 -4,260 -3,810               
      net increase in cash, cash equivalents and current financial assets compared to year-end 2023 and 2022
    		   48,630,750                          
      cash and cash equivalents and current financial assets at the end of the period
    		   843,591,750   3,104,466,000    2,007,513     2,855,384 2,336,728             
      income from investment in joint venture
    		     -1,619,000 -1,792,000 -1,788,000 -743,000 -1,619,000 -261,000                   
      operating income
    		     -102,094,000 -93,421,000 -138,624,000 -80,588,000 -102,094,000 -103,743,000 -114,432,000    -222,726,000 -348,746,000   -13,000          
      yoy
    		     0.00% -9.95% 21.14%    -48.62%    1713176.92%              
      qoq
    		     9.28% -32.61% 72.02% -21.06% -1.59% -9.34%     -36.14%              
      operating margin %
    		NaN% NaN% NaN% NaN% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% -Infinity% -70.13% NaN% 0% -0.01% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN%  
      loss for the period before taxes
    		     -83,861,000 -74,350,000 -61,178,000 -83,279,000 -83,861,000 -76,178,000 -41,238,000                  
      income tax benefit/
    		     -10,507,000 12,753,000                       
      net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2022 and 2023
    		                             
      loss for the period
    		      -61,597,000 -99,172,000 -72,642,000 -94,368,000 -28,871,000 -38,613,000    -227,187,000              
      loss for the period attributable to:
    		                             
      weighted-average number of shares outstanding
    		 61,034,202,000 60,983,325,000 59,855,585,000,000 60,087,498,000 55,828,239,000 59,309,996,000 59,118,827,000 58,128,233,000 55,828,239,000 55,555,186,000 55,364,124,000  55,203,655,000 54,802,339,000 52,084,335,000 51,075,827,000 51,075,827,000 50,638,702,000 49,946,515,000 38,619,121,000 44,717,568,000 43,476,103,000 38,619,121,000 38,619,121,000 37,764,237,000 24,609,536 21,756,366,000  
      basic and diluted
    		      -1,040                       
      net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2023 and 2022
    		      -75,378,000                       
      income tax benefit /
    		       -37,994,000                      
      loss for the year attributable to:
    		                             
      basis and diluted
    		       -1,680                      
      net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2022 and 2021
    		          -185,035                   
      basis and diluted loss per share
    		        -1.25 -1.69 -0.52                   
      net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2021 and 2022
    		                             
      ●
    		                             
      income tax benefit
    		          47,307,000 2,625,000                  
      loss from investment in joint venture
    		           -677,000                  
      exchange gains
    		           60,259,000           199,000 6,066,000  2,486,000  -854,000  
      basic loss per share
    		           -0.7                  
      diluted loss per share
    		           -0.7                  
      net increase in cash, cash equivalents and current financial assets compared to year-end 2021 and 2020
    		                             
      cash, cash equivalents and current financial assets at the end of the period
    		            596,385,250      2,730,997,000 2,907,355,000 451,010,750 1,804,043,000        
      operating income/
    		            -151,476,750 -208,637,000 -174,544,000               
      net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2021 and 2020
    		            12,203,250                 
      ​
    		                             
      financial expenses
    		               -953,000              
      income before taxes
    		               -230,072,000 -399,743,000   -29,249,000          
      income tax (expense) / benefit
    		               2,885,000              
      basic and diluted loss per share
    		               -4.36 -7.99      -4.73 -4.22  -1.19  -0.38  
      net increase/(decrease) in cash and cash equivalents and current financial assets compared to year-end 2021 and 2020
    		               518,656              
      revenue
    		                497,277,000  470,398,000 158,155,000          
      yoy
    		                             
      qoq
    		                  197.43%           
      financial income/
    		                -944,000  -745,000 -420,000 15,958,000 -1,683,000        
      income tax expense
    		                -8,522,000             
      loss for the year
    		                -408,265,000             
      net increase in cash and cash equivalents and current financial assets compared to year-end 2020 and 2019
    		                340,276             
      change in fair value on non-current financial assets
    		                  11,152,000 11,152,000 20,000 1,076,000 848,000       
      operating income /
    		                  95,123,000           
      profit / (loss) before taxes
    		                  76,003,000           
      profit / (loss) for the period
    		                  63,167,000           
      basic profit /
    		                  1,250           
      diluted profit /
    		                  1,170           
      net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2020 and 2019
    		                  734,545,000 910,903,000          
      exchange gain/
    		                   -28,817,000 -13,974,000 -55,896,000        
      income taxes
    		                   -11,184,000          
      loss for the period and total comprehensive loss
    		                   -40,433,000          
      basic and diluted profit/
    		                   -810 -2,030 -8,120        
      net increase in cash, cash equivalents and current financial assets compared to year-end 2019
    		                    117,055,750 468,223,000        
      equity and liabilities
    		                             
      equity
    		                             
      equity attributable to owners of the parent
    		                             
      share capital
    		                             
      share premium
    		                      2,043,653,000   828,162,000  430,518,000  
      accumulated losses
    		                      -538,205,000   -214,724,000  -100,568,000  
      other reserves
    		                      106,295,000   48,146,000  11,764,000  
      total equity
    		                             
      deferred tax liabilities
    		                      871,000       
      non-current liabilities
    		                         241,360,000  25,000  
      provisions for employee benefits
    		                      64,000   7,000  25,000  
      non-current lease liabilities
    		                      4,669,000   3,686,000    
      deferred revenue — non-current
    		                      202,560,000   237,667,000    
      total non-current liabilities
    		                      207,293,000       
      current liabilities
    		                         102,388,000  25,952,000  
      current lease liabilities
    		                      2,256,000   1,078,000    
      trade and other payables
    		                      127,850,000   55,068,000  15,285,000  
      tax liabilities
    		                      431,000   378,000    
      deferred revenue — current
    		                      67,294,000   45,864,000    
      total current liabilities
    		                      197,831,000       
      total liabilities
    		                             
      total equity and liabilities
    		                             
      loss before taxes
    		                             
      loss for the year and total comprehensive loss
    		                             
      loss for the year and total comprehensive loss attributable to:
    		                             
      changes in fair value on financial assets
    		                       1,096,000      
      current tax liabilities
    		                           597,000  
      deferred revenue
    		                           10,070,000  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-06-30 2024-12-31 2024-06-30 2024-02-29 2023-12-31 2023-06-30 2022-12-31 2022-06-30 2021-12-31 2021-06-30 2020-07-30 2020-06-30 2020-02-27 2019-12-31 2019-06-30 2018-12-31 2018-08-31 2017-12-31 2017-08-01 
                         
        assets
      		                   
        non‑current assets
      		                   
        property, plant and equipment
      		45,795,000 43,517,000 36,931,000 22,675,000 22,675,000 14,676,000 16,234,000 14,244,000 15,844,000 11,394,000 8,801,000 8,801,000 8,167,000 8,167 5,887,000 824 676,000  882,000 
        intangible assets
      		218,977,000 181,445,000 141,774,000 125,228,000 125,228,000 189,857,000 174,901,000 171,294,000 171,684,000 175,173,000 40,945,000 40,945,000 40,161,000 40,161 35,474,000 56 13,000  12,000 
        deferred tax assets
      		899,607,000 924,299,000                  
        research and development incentive receivables
      		100,467,000 94,854,000 91,237,000 76,706,000 76,706,000 59,976,000 47,488,000 37,041,000         158,000  163,000 
        investment in a joint venture
      		10,681,000 9,268,000                  
        prepaid expenses
      		23,643,000 23,643,000 47,327,000 47,327,000 47,327,000 47,327,000 76,022,000 82,310,000 58,946,000 62,397,000 10,864,000 10,864,000 9,022,000 9,022 8,326,000 2,995 2,338,000  2,360,000 
        other non-current assets
      		46,683,000 42,393,000 34,276,000 39,662,000 39,662,000 39,232,000 40,894,000 43,100,000 54,876,000        125,000   
        total non‑current assets
      		1,345,853,000 1,319,419,000 532,770,000  418,721,000 502,277,000 360,064,000 319,946,000 307,303,000 348,359,000    60,120 49,263,000 6,015 4,104,000   
        current assets
      		                   
        inventories
      		340,621,000 407,233,000 326,460,000 310,550,000 310,550,000 201,112,000 228,353,000 135,711,000 109,076,000 59,217,000 4,977,000 4,977,000        
        trade and other receivables
      		1,197,070,000 904,471,000 652,875,000 496,687,000 496,687,000 353,232,000 275,697,000 112,392,000 38,221,000 12,051,000 8,561,000 8,561,000 28,115,000 28,115 5,277,000 2,886 2,842,000  4,265,000 
        financial assets
      		1,842,200,000 1,878,890,000 1,664,100,000 1,131,000,000 1,131,000,000 886,401,000 1,391,808,000 1,230,105,000         168,907,000  97,896,000 
        cash and cash equivalents
      		2,085,976,000 1,499,936,000 1,438,247,000 2,048,844,000 2,048,844,000 1,110,567,000 800,740,000 1,367,288,000 1,334,676,000 1,581,893,000 1,201,443,000        75,533,000 
        total current assets
      		5,829,739,000 4,883,103,000 4,263,788,000 4,123,737,000 4,123,737,000 2,691,514,000 2,774,197,000 2,929,343,000 2,542,971,000 2,864,663,000 1,957,577,000  1,373,219,000 1,373,219 959,879,000 572,443 366,804,000  181,909,000 
        total assets
      		7,175,592,000 6,202,522,000 4,796,558,000 4,542,458,000 4,542,458,000 3,193,791,000 3,134,261,000 3,249,289,000 2,850,274,000 3,213,022,000 2,022,449,000       370,908,000 185,486,000 
        the accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.
      		                   
        equity and liabilities
      		                   
        equity
      		                   
        equity attributable to owners of the parent
      		                   
        share capital
      		7,264,000 7,227,000 7,118,000 7,058,000  6,698,000  6,603,000  6,202,000 4,711,000       3,217,000 2,687,000 
        share premium
      		6,025,789,000 5,948,916,000 5,747,441,000 5,651,497,000  4,374,291,000  4,272,495,000  3,442,742,000 2,043,653,000 2,043,653,000 1,308,539,000 1,308,539 828,162,000 673,454 430,518,000 430,518,000 218,878,000 
        translation differences
      		133,348,000 126,832,000 128,935,000 131,543,000  130,042,000  128,691,000  133,161,000          
        accumulated losses
      		-1,156,977,000 -1,571,804,000 -2,437,375,000 -2,404,844,000  -2,233,029,000  -1,836,133,000  -928,764,000  -538,205,000 -332,568,000 -332,568 -214,724,000 -169,603 -100,568,000   
        other reserves
      		1,086,328,000 987,112,000 816,128,000 712,253,000  580,049,000  398,615,000  298,592,000 106,295,000 106,295,000 70,499,000 70,499 48,146,000 30,947 11,764,000  9,376,000 
        total equity
      		6,095,752,000 5,498,283,000 4,262,247,000 4,097,507,000  2,858,051,000  2,970,271,000  2,951,933,000 1,616,454,000       344,931,000 150,254,000 
        non-current liabilities
      		            222,636,000 222,636 241,360,000 7 25,000  1,000 
        provisions for employee benefits
      		2,368,000 1,803,000 1,581,000 1,449,000  1,011,000  546,000  227,000 64,000 64,000 64,000 64 7,000 7 25,000  1,000 
        lease liabilities
      		35,568,000 32,520,000 28,107,000 15,354,000  8,044,000  6,208,000            
        total non-current liabilities
      		37,936,000 34,323,000 34,682,000 21,958,000  17,949,000  14,417,000  17,046,000 207,293,000 207,293,000        
        current liabilities
      		            159,957,000 159,957 102,388,000 40,056 25,952,000  35,231,000 
        trade and other payables
      		1,016,160,000 649,993,000 479,829,000 414,013,000  309,985,000    239,439,000 127,850,000 127,850,000 85,301,000 85,301 55,068,000 37,072 15,285,000  13,066,000 
        tax liabilities
      		18,160,000 13,390,000 13,947,000 4,334,000  4,608,000  3,415,000  1,154,000 431,000 431,000 344,000 344 378,000 823    
        total current liabilities
      		1,041,904,000 669,916,000 499,629,000 422,993,000  317,791,000  264,601,000  244,043,000 197,831,000 197,831,000        
        total liabilities
      		1,079,840,000 704,239,000 534,311,000 444,951,000  335,740,000  279,018,000  261,089,000 405,995,000       25,977,000 35,232,000 
        total equity and liabilities
      		7,175,592,000 6,202,522,000 4,796,558,000 4,542,458,000  3,193,791,000  3,249,289,000  3,213,022,000 2,022,449,000        185,486,000 
        deferred tax liabilities
      		  4,994,000 5,155,000  8,894,000  7,663,000  12,388,000 871,000 871,000        
        deferred tax asset
      		  174,626,000 97,211,000 97,211,000 138,767,000 79,222,000 54,267,000 32,191,000 16,254,000          
        investment in joint venture
      		  6,599,000 9,912,000 9,912,000 12,443,000 1,323,000             
        non-current assets
      		                   
        total non-current assets
      		   418,721,000       64,872,000  60,120,000      3,577,000 
        deferred revenue
      		                10,070,000 10,070,000 21,568,000 
        trade payables and other payables
      		       257,694,000            
        research and development incentive receivables — current
      		          377,000 377,000 261,000 261 301,000 301    
        financial assets — current
      		        1,002,052,000 1,149,104,000 731,355,000 731,355,000 1,004,539,000 1,004,539 776,490,000 283,529    
        research and development incentive receivables — non-current
      		        32,707,000 26,080,000 11,050,000 11,050,000 8,566,000 8,566 6,047,000 4,883    
        lease liabilities — non-current
      		         4,431,000   4,540,000 4,540      
        deferred revenue — non-current
      		          202,560,000 202,560,000 218,032,000 218,032 237,667,000     
        lease liabilities — current
      		         3,450,000   1,974,000 1,974      
        deferred revenue — current
      		          67,294,000 67,294,000 72,338,000 72,338 45,864,000 2,161    
        ​
      		                   
        restricted cash - non-current
      		         1,437,000          
        financial assets - non-current
      		         118,021,000          
        restricted cash — non-current
      		          632,000 632,000 630,000 630 356,000 251    
        financial assets — non-current
      		          3,444,000 3,444,000 2,596,000 2,596 1,499,000 1    
        non-current lease liabilities
      		          4,669,000 4,669,000   3,686,000     
        current lease liabilities
      		          2,256,000 2,256,000   1,078,000     
        restricted cash — current
      		              1,692,000 1,692    
        restricted cash
      		                1,692,000  1,692,000 
        current tax liabilities
      		                597,000  597,000 
        condensed consolidated statement of financial position:
      		                   
        cash, cash equivalents and current financial assets
      		                   
        accumulated deficits
      		                  -80,687,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD 
         
          operating profit
        		 
          adjustments for non-cash items
        		 
          amortization of intangible assets
        		 
          depreciation of property, plant and equipment
        		 
          provisions for employee benefits
        		 
          expense recognized in respect of share-based payments
        		 
          fair value gains on financial assets at fair value through profit or loss
        		 
          loss from investment in a joint venture
        		 
          other non-cash expenses
        		 
          movements in current assets/liabilities
        		 
          decrease in trade and other receivables
        		 
          decrease in inventories
        		 
          decrease in other current assets
        		 
          increase in trade and other payables
        		 
          movements in non-current assets/liabilities
        		 
          decrease in other non‑current assets
        		 
          net cash flows from/(used) in operating activities, before interest and taxes
        		 
          interest paid
        		 
          income taxes received
        		 
          net cash flows from/(used) in operating activities
        		 
          purchase of intangible assets
        		 
          purchase of property, plant and equipment
        		 
          purchase of current financial assets
        		 
          sale of current financial assets
        		 
          interest received
        		 
          investment in a joint venture
        		 
          net cash flows from/(used) in investing activities
        		 
          principal elements of lease payments
        		 
          payment of employee withholding taxes relating to restricted stock unit awards
        		 
          proceeds from exercise of stock options
        		 
          net cash flows from financing activities
        		 
          increase in cash and cash equivalents
        		 
          cash and cash equivalents at the beginning of the period
        		 
          exchange gains on cash and cash equivalents
        		 
          cash and cash equivalents at the end of the period
        		 
          the accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.
        		 
          decrease in non-current prepaid expense
        		 
          net cash flows from operating activities, before interest and taxes
        		 
          net cash flows from operating activities
        		 
          net cash flows from investing activities
        		 
          proceeds from issue of new shares, gross amount
        		 
          issue costs paid
        		 
          exchange gains from currency conversion on proceeds from issue of new shares
        		 
          cash and cash equivalents at the beginning of the year
        		 
          cash and cash equivalents at the end of the year
        		 
          operating loss
        		 
          loss from investment in joint venture
        		 
          investment in joint venture
        		 
          non-cash revenue
        		 
          increase in deferred revenue — current
        		 
          decrease in other non-current assets
        		 
          increase in deferred revenue — non-current
        		 
          income taxes paid
        		 
          decrease in current financial assets
        		 
          purchase of current financial investments
        		 
          sale of current financial investments
        		 
          net cash flows (used in) / from investing activities
        		 
          exchange gain/(losses) from currency conversion on proceeds from issue of new shares
        		 
          increase/decrease (-) in cash and cash equivalents
        		 
          operating income
        		 
          income from investment in joint venture
        		 
          ​
        		 
          (increase)/decrease in trade and other receivables
        		 
          (increase)/decrease in inventories
        		 
          (increase)/decrease in other current assets
        		 
          increase/(decrease) in trade and other payables
        		 
          increase/(decrease) in deferred revenue — current
        		 
          (increase)/decrease in other non‑current assets
        		 
          (increase)/decrease in non-current prepaid expense
        		 
          increase/(decrease) in deferred revenue — non-current
        		 
          net cash flows used in operating activities, before interest and taxes
        		 
          net cash flows used in operating activities
        		 
          (increase)/decrease in current financial assets
        		 
          net cash flows from / (used in) investing activities
        		 
          exchange (losses)/gains from currency conversion on proceeds from issue of new shares
        		 
          increase/(decrease) in cash and cash equivalents
        		 
          exchange gains/(losses) on cash and cash equivalents
        		 
          decrease in non‑current prepaid expenses
        		 
          cash flows from operating activities
        		 
          exchange gain from currency conversion on proceeds from issue of new shares
        		 
          payment on employee withholding taxes related to restricted stock unit awards
        		 
          exchange gains on cash & cash equivalents
        		 
          operating result
        		 
          cash flows (used in) / from operating activities
        		 
          net cash flows (used in) / from operating activities
        		 
          decrease in financial assets — current
        		 
          net cash flows from/used in (-) financing activities
        		 
          fair value gains on non-current financial assets at fair value through profit or loss
        		 
          increase in deferred revenue – current
        		 
          increase in deferred revenue – non-current
        		 
          cash flows (used in)/from operating activities
        		 
          decrease in financial assets – current
        		 
          proceeds from issue of new shares
        		 
          net cash flows (used in) / from financing activities
        		 
          net increase in cash & cash equivalents
        		 
          increase/(decrease) in deferred revenue – current
        		 
          (increase)/decrease in deferred revenue – non-current
        		 
          (increase)/decrease in financial assets – current
        		 
          exchange gains/(losses) on cash & cash equivalents
        		 
          loss on disposal of fixed assets
        		 
          decrease in deferred revenue – non-current
        		 
          cash flows (used in) / from investing activities
        		 
          cash flows (used in) / from financing activities
        		 
          payment of lease liabilities
        		 
          increase in current deferred revenue
        		 
          decrease in non-current deferred revenue
        		 
          expense recognized in respect of share‑based payments
        		 
          increase in deferred revenue
        		 
          proceeds from issue of shares
        		 
          condensed consolidated statement of cash flows:
        		 
          cash and cash equivalents at beginning of the period
        		 
          effect of exchange rate differences on cash and cash equivalents
        		 
          cash and cash equivalents at end of the period
        		 
          amortisation of intangible assets
        		 
          depreciation and impairment of property, plant and equipment
        		 
          interests paid
        		 
          net cash flows generated (used in) / from operating activities
        		 
          cash flows from investing activities
        		 
          investment in current financial assets
        		 
          disposal of current financial assets
        		 
          cash flows from financing activities
        		 
          transaction costs for equity issue
        		 
          net increase in cash and cash equivalents
        		 
          exchange gains